Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-64041809 in mCRPC
NCT02625857Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2015
- Primary completion
- Jul 2018
- Modality
- Therapeutic Vaccines, Live Attenuated Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of opolimogene capmilisbac in metastatic castration-resistant prostate cancer (mCRPC) (2 cohorts), sponsored by Janssen Pharmaceutical. Primary endpoints: Incidence of Dose-limiting-toxicity at 21 days, Antigen-specific T-cell Response at 1 year and 1 more. Started Dec 2015; status: completed.
02
Drugs
opolimogene capmilisbac
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT02625857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02625857.